Clinical trial Recruiting at 1 site Interventional Ages 18 to 75 Women only

Same-day awake mastectomy with immediate prepectoral implant reconstruction

Official title: Evaluation of Safety, Quality of Life, Cost and Environmental Impact of Day Surgery in Mastectomy and Prepectoral Reconstruction - Awake MAstectomy in Day Surgery With Immediate Prepectoral Implant Reconstruction and Muscle Sparing

Run by University of Rome Tor Vergata · NCT07510698 · Data updated 2026-11-12

This project tests whether the AMADeuS care pathway—awake same-day mastectomy with prepectoral implant reconstruction, opioid-sparing anesthesia, and telemedicine follow-up—controls pain and is as safe as usual hospital care for women having mastectomy.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexWomen only
Enrollment100 (estimated)
SponsorUniversity of Rome Tor Vergata
Academic / other
Locations1 site (Rome, Rome)
StatusRecruiting
StartedApril 1, 2026
Main results expectedMarch 1, 2028
Study endsApril 1, 2028
Registry record updatedApril 3, 2026
Trial IDNCT07510698 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Biologically female patients aged 18–75 having nipple- or skin-sparing mastectomy with planned immediate prepectoral implant or tissue expander reconstruction, with BMI <35, ASA class I–III, adequate skin flap and no severe prior chest radiotherapy, and who have home autonomy, a caregiver for 24 hours, and distance from hospital compatible with day-surgery discharge are ideal candidates.

Probably not a fit

Patients who need more complex reconstruction, have inadequate skin flap vascularity, BMI ≥35, severe prior chest radiotherapy, ASA IV comorbidity, lack home support or cannot complete telemedicine follow-up are unlikely to benefit from the same-day awake pathway.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional comparison follows women undergoing nipple- or skin-sparing mastectomy with immediate prepectoral implant or tissue expander reconstruction who receive either the AMADeuS perioperative pathway or usual hospital care. The AMADeuS pathway combines awake surgery with monitored anesthesia care, enhanced recovery (opioid-sparing) protocols, same-day discharge when safe, and structured telemedicine follow-up. Outcomes include pain control in the first 48 hours, safety over 30 days, patient-reported quality of life and satisfaction, hospital resource use, and environmental impact. Researchers will compare these outcomes between the two care pathways to see if the AMADeuS approach can maintain safety and pain control while reducing resource use and environmental footprint.

Why it matters

Potential benefit: If successful, the AMADeuS pathway could allow eligible women to have awake same-day mastectomy with immediate prepectoral reconstruction while maintaining pain control and safety, reducing hospital stays and resource use.

How similar studies have gone: Existing studies suggest same-day mastectomy with immediate reconstruction can be feasible and safe in selected patients, but combining awake monitored anesthesia care with a standardized ERAS day-surgery pathway and environmental outcomes is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
\*\*Inclusion Criteria:\*\*

* Biologically female participants aged 18 to 75 years
* Oncologic or prophylactic indication for nipple-sparing mastectomy or skin-sparing mastectomy with immediate prepectoral reconstruction using a definitive implant or tissue expander, including early breast cancer or a high-risk genetic condition such as BRCA
* Eligible for prepectoral reconstruction based on clinico-anatomic criteria, including adequate skin flap thickness, no relevant vascular compromise, body mass index less than 35, and no severe prior chest radiotherapy
* American Society of Anesthesiologists (ASA) class I to III
* Eligible for day surgery, defined by home autonomy, caregiver availability during the first 24 hours after surgery, and distance from the hospital compatible with home management
* Able and willing to complete telemedicine follow-up, including completion of protocol-required patient-reported outcome measures
* Written informed consent provided

\*\*Exclusion Criteria:\*\*

* Chronic opioid use or treatment for pre-existing chronic pain that could interfere with assessment of the primary postoperative pain endpoint
* Contraindications to locoregional anesthesia techniques or to the awake/monitored anesthesia care protocol, including allergy to local anesthetics, coagulation disorders, or inability to cooperate during surgery
* Body mass index 35 or greater, or anatomic conditions contraindicating prepectoral reconstruction
* Previous high-dose chest radiotherapy with significant tissue compromise
* Pregnancy or breastfeeding
* Inability to guarantee planned follow-up or lack of adequate home support
* Psychiatric or cognitive conditions preventing correct completion of patient-reported outcome measures

Where it's running

  • PTV Policlinico Tor Vergata University Hospital
    Rome, Rome, Italy
    Recruiting

Study contacts

  • Principal investigator: Gianluca Vanni, Associate Professor — University of Rome Tor Vergata
  • Study coordinator: Gianluca vanni, Associate Professor
  • Email: vanni_gianluca@yahoo.it
  • Phone: +393395685883

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Combined PECS II and PIP blocks vs TPVB for post-mastectomy pain relief

    This trial tests whether a combination of PECS II and superficial PIP blocks can provide better or similar pain relief after mastectomy compared with the standard thoracic paravertebral block.

    Recruiting Dharmais National Cancer Center Hospital · Jakarta, DKI Jakarta · NCT07738770

  • Using indocyanine green to find sentinel lymph nodes during mastectomy

    This pilot will test whether injecting indocyanine green and using fluorescence during mastectomy can find sentinel lymph nodes in women with clinically node-negative invasive breast cancer.

    Recruiting at 2 sites St. Antonius Hospital · Zwolle, Overijssel and 1 other locations · NCT07362485

  • AI-supported education for patients undergoing mastectomy

    This study is testing whether an AI-supported education program can help reduce fear and anxiety in women getting a mastectomy for breast cancer compared to standard education.

    Recruiting Bezmialem Vakif University · Istanbul, Bakirköy · NCT06796166

  • Comparing two nerve-block options to reduce pain after total mastectomy.

    This test tries whether a PECS-II block given before surgery or a pectoral block given during surgery, using bupivacaine or liposomal bupivacaine, provides better pain control after total mastectomy for breast cancer or high-risk patients.

    Recruiting Phase 4 University of Cincinnati · Cincinnati, Ohio · NCT06574022

  • Upfront treatment for breast cancer with nodal metastases

    This study is testing if starting treatment with surgery and targeted therapy can help women with early-stage breast cancer that has spread to their lymph nodes live longer and have fewer recurrences.

    Recruiting at 3 sites Phase 2 Cedars-Sinai Medical Center · Los Angeles, California and 2 other locations · NCT06092892

  • Identifying risk factors for seroma formation after breast surgery

    This study is trying to find out which patients are more likely to develop fluid buildup after breast surgery so that doctors can give better advice and care to prevent it.

    Recruiting University Hospital Augsburg · Augsburg, Bavaria · NCT05899387

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.